Dr. Marcom is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
20 Duke Medicine Circle
Durham, NC 27710Phone+1 919-660-9672- Is this information wrong?
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1992 - 1995- Duke University HospitalResidency, Internal Medicine, 1989 - 1992
Baylor College of MedicineClass of 1989
Certifications & Licensure
NC State Medical License 1991 - 2024- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Join now to see all
Clinical Trials
- A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel Start of enrollment: 2003 Oct 01
- Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC Start of enrollment: 2000 Jan 01
- Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer Start of enrollment: 2008 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 26 citationsMultiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.Susana Garcia-Recio, Toshinori Hinoue, Gregory L Wheeler, Benjamin J Kelly, Ana C Garrido-Castro, Tomas Pascual, Aguirre A De Cubas, Youli Xia, Brooke M Felsheim, Marn...> ;Nature Cancer. 2023 Jan 1
- 1 citationsPredictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions.Claire E P Smith, Paul K Marcom, Zahi Mitri, Naomi Y Ko> ;Breast Cancer Research and Treatment. 2022 Nov 1
- 13 citationsThe Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.Cynthia X Ma, Jingqin Luo, Rachel A Freedman, Timothy J Pluard, Julie R Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M Jones, Nancy U Lin, Eric P W...> ;Clinical Cancer Research. 2022 Apr 1
- Join now to see all
Press Mentions
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical TeamJuly 1st, 2021
Novel Combinations Key to Advancing HR+ Breast Cancer CareDecember 27th, 2016
Hospital Affiliations
Duke University HospitalDurham, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
